Get the latest buzz in the global pharmaceutical market here.
91Թ’s newly acquired manufacturing facility located at Plot No. A1, Phase l-A, Verna Industrial Estate, Verna, Goa - 403722 has successfully undergone inspection from German health authorities.
91Թ’s wholly owned subsidiary Time-Cap Laboratories, Inc. has received Establishment Inspection Report (EIR) from US Food & Drugs Administration for the audit conducted in October 2023. No 483’s were issued during the Audit.
91Թ’s wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.
91Թ has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed- Release Capsules USP, 20 mg (OTC).
India Ratings and Research Private Limited (a Fitch group company) has upgraded 91Թ’s bank facilities’ ratings as follows:-
Instrument Type | Size of Issue (million) |
Rating/Outlook | Rating Action |
---|---|---|---|
Fund-based limits | INR 1,000 | IND A+/Positive | Upgraded |
Non-fund-based limits | INR 770 | IND A1+ | Upgraded |
91Թ has received final approval from the US Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application ("ANDA") for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter ("OTC") bioequivalent of Advil Dual Action Tablets 250 mg/125 mg.
91Թ has received USFDA approval for Guaifenesin Extended-Release Tablets (OTC).
91Թ. has completed the acquisition of a manufacturing site from Tevapharm India in Plot No. Al, Phase l-A, Verna Industrial Estate, Verna, Goa 403722, India.